Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.

Health Technology Assessment

Type:

Extended Research Article Our publication formats
Authors:

Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A, Davenport C.
Journal:

Health Technology Assessment
Issue:

Volume: 6, Issue: 3
Published:

May 2002
Citation:

Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A et al. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002;6(3). https://doi.org/10.3310/hta6030
DOI:

https://doi.org/10.3310/hta6030